FSHD2

Clinical trials for FSHD2 explained in plain language.

Never miss a new study

Get alerted when new FSHD2 trials appear

Sign up with your email to follow new studies for FSHD2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for FSHD: phase 3 trial of AOC 1020 begins

Disease control Recruiting now

This study tests an experimental drug called AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 adults with a confirmed FSHD diagnosis who can still walk will receive either the drug or a placebo by I…

Matched conditions: FSHD2

Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated May 26, 2026 09:33 UTC

FSHD2

Get alerted when new FSHD2 trials appear

New hope for FSHD: phase 3 trial of AOC 1020 begins